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Abstract 
Mycobacteria acquire iron by producing siderophores called mycobactins, with an extremely high affinity complexation of 
Fe3+. The iron complex shows distinctive electrochemistry predicting 18 orders of magnitude greater affinity of the 
mycobactin for Fe3+ than Fe2+.  A heterogeneous standard rate constant, ks  of the order of 10
-5 cm s-1 confirms quasi 
reversible electrochemistry and based on the equilibrium in the presence of excess solution Fe3+/Fe2+ the oxidation and 
reduction peaks for the siderophore complex could be calibrated for ferric mycobactin J (FeMJ). FeMJ spiked urine 
collected from cows showed a matrix effect on the current peak height. For example, 240±15µM FeMJ was estimated in 
600µM spiked urine.  However, in the presence of excess solution Fe(acac)3 the same sample yielded an estimated 
580±25µM FeMJ. 
 
Keywords: Mycobacteria, Mycobactin, cyclic voltammetry, bovine assay 
DOI: 10.1002/elan.((will be filled in by the editorial sttaff)) 
1. Introduction 
There are more than 150 mycobacteria known, many of 
which are pathogenic. They generally show a high 
hydrophobicity with a complex lipid-rich cell wall 
architecture [1] that is not susceptible to normal 
antibiotics. The pathogenic species are responsible for a 
number of diseases, including tuberculosis (TB), Johne’s 
disease, Buruli ulcer and leprosy and may also play a role 
in chronic bowl diseases, allergies and immunity to other 
pulmonary infections [2]. 
In the most highly developed areas of the word the 
incidence of TB has been reduced, yet the bacterium 
(Mycobacterium tuberculosis, Mtb) continues to infect 
one-third of the global population with 8.6 million people 
falling ill and 1.3 million people killed in 2012 [3]. Only 
a very small percentage of human-mycobacteria 
interaction turn into full mycobacterial infection, but such 
progression is much more common in 
immunocompromised patients. This has led to a great 
number of clinical TB cases and deaths in populations 
that have high rates of Mtb and HIV coinfection and 
contributed to a global resurgence of TB [3,4] Areas with 
particularly high TB burdens include Sub-Saharan Africa 
and Southeast Asia. 
Bovine tuberculosis is caused by the bacterium 
Mycobacterium bovis, which can also infect humans and 
many other mammals including deer, goats, pigs, cats, 
dogs and badgers. There are many species of 
environmental atypical mycobacterioses. M. avium subsp. 
paratuberculosis causes Johne's disease in ruminants and 
has been proposed as a cause of Crohn's disease in 
humans[5]. Environmental mycobacteria are not obligate 
pathogens but can be found as saprophytes, commensals, 
and symbionts. Therefore, the detection and control of M. 
tuberculosis complex organisms and atypical 
mycobacterioses is important.  
In thinking about detection, it is worth considering that 
iron is a key nutrient, necessary for metabolic function 
and division. Mycobacteria acquire iron by producing 
siderophores called mycobactins to harvest iron from 
their environment. Mycobactins from different 
mycobacteria exhibit structural variation in their alkyl 
substitutions and chiral centers, but share the same core 
salicylate-oxazoline structure, which produces 
hexadentate iron-chelation chemistry with an extremely 
high affinity complexation of Fe3+ [6,7]. 
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There have been several assays created in order to detect 
or measure mycobactin in different contexts. The ligand 
to metal charge transfer, indicative of iron-containing 
compounds, results in a characteristic absorbance at 
450 nm; the desferri- forms lack this 450 nm absorbance 
peak [8]. Mycobactins also have a major absorbance peak 
at 220 nm, indicative of amide and aromatic groups [8]. 
This allows for simple differentiation between the ferric 
and desferri- forms and has been employed by Gobin and 
coworkers in combination with reverse-phase high-
performance liquid chromatography (HPLC) and mass 
spectrometry to purify and identify mycobactins [9]. 
Another common assay utilizes chrome azurol S-shuttle 
solution (CAS) detect production of any iron-chelating 
siderophores [10]. When the siderophores chelate iron, 
removing it from the dye complex, the dye changes from 
blue to orange. This can be observed as an absorbance 
extinction at 630 nm. Koedam et al. improved on this 
method by combining isoelectric focusing with CAS 
overlay for siderophore detection and differentiation. 
Another dye-based method for catechol-based 
siderophores is to use the Arnow assay [11], however this 
is not typically employed to detect hydroxamate 
siderophores such as mycobactin. These methods are 
useful for certain in vitro applications, however they lack 
the versatility required for routine screening. 
A bioassay based upon the growth of mycobactin-
dependent M. avium subsp. paratuberculosis was 
developed by Lambrecht and Collins [12], but this assay 
failed to detect the presence of mycobactin in infected 
tissue samples with an estimated sensitivity of 6 nM and 
a readout time of 21 days. Nevertheless, the features of 
mycobactins and their Fe3+ complexation offer scope for 
a common assay approach and some potential for 
distinction according to substitution. 
We have sought to investigate the potential for a versatile 
electrochemical assay for mycobactin that may, in turn, 
contribute to techniques for an Mtb infection assay. This 
proof-of-concept assay takes advantage of the specific 
electrochemical properties of mycobactin-chelated iron 
for detection.  
2. Experimental 
2.1 Materials 
Purified ferric mycobactin J (FeMJ) was purchased from 
Allied Monitor. Potassium chloride, lithium chloride 
tris(hydroxymethyl)aminomethane (TRIS), phosphate 
buffered saline tablet (PBS), hydrochloric acid, sodium 
hydroxide, chloroform, DMSO, diethyl ether and ethanol 
were purchased from Sigma-Aldrich. Reagents were used 
as received without further purification and aqueous 
solutions were prepared in milli-Q water (resistance 18.2 
MΩ/cm). 
2.2 Deferration of Mycobactin 
Deferration of the FeMJ was accomplished by dissolving 
2 mg of mycobactin in 10 mL of chloroform and shaking 
with 10 mL of 5 M hydrochloric acid. The organic phase 
was then separated and dried under vacuum to give 
desferri mycobactin J (DFMJ). 
2.3 Electrochemical Experiments 
A 3 mm diameter glassy carbon electrode (GCE) was 
purchased from Bioanalytical Systems, Inc. (BASi) The 
electrode surface was prepared by polishing successively 
with 1.0 µm and 0.05 µm alumina powder using 
MicroCloth polishing cloths (Buehler) affixed to a glass 
base. Alumina residue was subsequently removed by 
oxidative cleaning at 0.8 V vs. Ag/AgCl in aqueous 1 M 
sodium hydroxide and 1 M potassium chloride [13]. 
Measurements were performed on a Princeton Applied 
Research 263A potentiostat and a PC running CorrWare 
software. Unless otherwise noted, all figures and 
calculations were made using cyclic voltammograms at 
0.2 V/s scan rate. For high-speed cyclic voltammetry a 
Solartron 1286 potentiostat was used in analog mode to 
drive the potential, while a PicoScope 4224 was used for 
data acquisition. A custom Matlab program was written 
to process the high-speed cyclic voltammetry data. The 
final electrochemical configuration consisted of a 
platinum wire counter electrode, silver wire pseudo 
reference electrode, and GCE working electrode in either 
DMSO containing 0.1 M LiCl or 50% ethanol solution 
containing 0.1 M KCl supporting electrolyte. Oxygen 
was removed from the solution by bubbling nitrogen gas 
for at least 10 min and maintaining a unidirectional gas-
flow environment; longer times were required to 
adequately deoxygenate desferri mycobactin solutions. 
2.4 Spiking of Water and Urine Samples 
25 mL of either purified, deionized water or female 
bovine urine was spiked with a stock solution of 5 mM 
FeMJ in DMSO to give final concentrations of 5 µM 
FeMJ and 0.1% of the respective solvent. The samples 
were then subjected to chromatography as outlined 
below. 
 
 
 
Page 2 of 9
Wiley-VCH
ELECTROANALYSIS
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
Full Paper                                                            ELECTROANALYSIS 
2.5 Chromatographic Concentration of Mycobactin 
Chromatographic concentration was performed using 
reverse-phase Waters Sep-Pak tC18 cartridges containing 
50 mg of sorbent, bead size of 37-55 µm, pore size of 
125 Å, and bed volume of 0.13 mL. Elution was 
performed with 3×0.5 mL of diethyl ether and the eluate 
was subsequently dried under vacuum. 
Spectrophotometric analysis was done after dissolving 
the residue in 0.75 mL methanol or electrochemical 
analysis was performed after dissolving the residue in 
0.1 mL DMSO containing 0.1 M LiCl.  
2.6 Bovine Urine Experiments 
For the bovine urine experiments, urine was collected 
from three female cows from the University of 
Cambridge Department of Veterinary Medicine dairy 
herd. 25 mL samples were either spiked with 2 µM FeMJ 
and 0.1% DMSO (final concentration), or left unspiked 
and frozen at -80°C until chromatography. 
Scheme 1. Structure of MbJ and MbT shown with pKa values 
for its iron-chelating ligands 
3. Results and Discussion 
The core structure of mycobactin is shown in scheme 1. 
Each species of mycobacteria has a defined set of R2-6 
substituents, while the alkyl chain at R1 can vary in 
length (C14-20) and degree of unsaturation. It is common 
for the alkyl chain to contain a cis double bond in the α-β 
position [14]. Both the cyclic and linear lysine residues 
are N6-hydroxylated to form the two hydroxamate metal 
coordination sites. These, together with an oxazoline-
phenolate coordination site, serve to make mycobactin a 
hexadentate metal coordinator with an extremely high 
formation constant for complexation for Fe3+ (4×1026 M-
1) [6].  
Ferric mycobactin J (FeMJ) was chosen as the model 
mycobactin for these experiments due to its ready 
availability in a relatively pure form and similarity to 
mycobactin T in its core structure and iron-coordination 
ligands (see scheme 1), as well as its importance in 
veterinary medicine [5]. 
3.1 Electrochemistry of mycobactin J 
Lipophilic mycobactin J with or without iron is virtually 
insoluble in aqueous media, so figure 1a shows the 
current-voltage curves of the siderophore in 1:1 
ethanol:water and dimethyl sulfoxide (DMSO). As shown 
by the method of Harrington et al. [15], the relationship 
between the reduction potential of the siderophore 
complex and the reduction of Fe3+ in solution is related to 
the ratio of formation constants according to the Nernst 
equation: 
 
 
Equation 1 
Fig. 1. Cyclic voltammograms at 200mV s-1 (a) of FeMJ and 
DFMJ in 50% ethanol/water with 0.1 M KCl; (b) FeMJ 
(640µM) in DMSO with 0.1 M LiCl; (c) background-subtracted 
CVs of FeMJ (640µM) in DMSO with 0.1 M LiCl at different 
scan rates (25mV/s – 3.2V/s). 
where  is the standard potential for reduction of the 
complex, Eaq is the standard potential for reduction of 
Fe3+ in solution, and βIII and βII are the formation 
Ecomplex
0
Ecomplex
0 − Eaq = −59.16mV log
βIII
βII
 
 
 



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constants for the complex with Fe3+ and Fe2+ 
respectively. From the data obtained, this yields a βIII/βII 
ratio of 1.9×1018, signifying 18 orders of magnitude 
greater affinity of the mycobactin for Fe3+ than Fe2+, in 
agreement with previously published estimations for a 
water-soluble analogue of mycobactin [15]  and in line 
with its expected high affinity for Fe3+ (4×1026 M-1) [6]. 
These affinity kinetics are essential to the iron trafficking 
mechanism, whereby mycobactin bound ferric ion is 
transported though the cell wall where iron is removed by 
its reduction to Fe2+ [15,16].   
Scheme 2. Redox equilibria for FeMJ with associated Fe2+/3+ 
complexation steps, producing an EC electrochemical 
mechanism.  
Fig.2 (a) CV reduction peak current versus FeMJ concentration 
at different scan rates. (b) ip/ν
1/2 versus ν1/2 shown for both the 
reduction and oxidation peaks of FeMJ at concentrations 0, 5, 
10, 20, 40, 80,160, 320, 640µM. Data recorded in DMSO, 
0.1 M LiCl 
Typical cyclic voltammograms (CVs) of FeMJ (Figure 1b 
and 1c) show a quasi-reversible redox couple, assigned to 
the mycobactin complexed Fe3+/Fe2+ couple, with 
midpoint potential -0.41 V vs. Ag/Ag+ (at 25 mV/s, 
0.64 mM in DMSO). Calibration curves obtained at 
different scan speeds (figure 2a, shown for the reduction 
peak), show that the peak height is proportional to 
concentration but with deviation from a good linear fit. If 
this would be a simple electron transfer limited by 
diffusion, ip/ν
1/2 should be independent of scan rate (ν), 
as given by a rearrangement of the Randles-Sevcik 
equation. Diagnostic plots of ip/ν
1/2 versus ν1/2 (figure 2b) 
were independent of scan rate at low concentration and 
high scan rate (black boxed area in figure 2b), but 
changed with scan rate at lower scan rates or higher 
concentrations (>150µM) with a slope increasing with 
concentration. This points to a coupled electrochemical-
chemical pathway. This would be anticipated for a 
reaction pathway also involving the affinity kinetics 
between Fe2+/3+ and the mycobactin.  
 
The presence of a competing chemical step following 
reduction is confirmed by ipa/ipc < 1 for all scan rates and 
concentrations. This can be interpreted by dissociation of 
the Fe2+ from the MJ complex upon reduction of Fe3+ (k2 
in scheme 2). Consistent with this, ipa/ipc increases 
(from~0.3 to ~0.8) with scan rate at low FeMJ 
concentrations. At fast scan rate the electrochemical 
oxidation of the iron-mycobactin complex competes with 
the rate of the dissociation, so the oxidation peak is 
recovered. For a given scan rate, ipa/ipc mostly increases 
with concentration, suggesting that Fe2+ dissociation is 
influenced by overall siderophore concentration, which 
could suggest intermolecular exchange of Fe2+.  
 
In order to determine whether the observed redox couple 
is attributable specifically to the ferric iron chelated by 
mycobactin, the iron was removed from FeMJ to create 
DFMJ as described in the materials and methods section. 
Cyclic voltammograms of DFMJ lacked the peaks 
characteristic of FeMJ, but upon titration of Fe(acac)3 
into the solution, the characteristic peaks returned (figure 
3a). Furthermore, upon oversaturation of the 1:1 iron-
binding ratio with DFMJ, the redox peaks shifted 
cathodically, indicating a shift in the equilibrium for the 
Fe2+/3+ MJ complex. Since the Fe(acac)3 redox couple lies 
at a higher potential (in figure 3a the reduction peak can 
be seen at -0.28 V with excess Fe(acac)3), then at the 
potential for FeMJ redox, Fe(acac)3 is reduced producing 
high Fe2+ concentrations near the electrode, driving the 
k2/k-2 equilibrium away from dissociation. This also 
results in ipa/ipc approaching unity at low scan rates.   
 
 
DFMJ + Fe3+
Fe3+MJ
+e
-e
Fe2+MJ
Fe2+  + DFMJ
k1 k-1 k2k-2
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3.2 Kinetics of FeMJ redox 
The quasi reversible behaviour of this iron complex is 
also indicated by the diagnostic plots of E versus log v 
(figure 3b and c) which yield slopes greater than 30 mV 
per decade for scan rates greater than 200 mV/s. 
Interestingly, at low scan rates, peak separation decreases 
with increase in concentration, lending support to the idea 
that Fe2+ dissociation is reversed in the presence of higher 
concentrations of FeMJ. Leading on from the theory 
developed by Nicholson and Shain [17], followed by 
Klingler and Kochi [18], apparent transfer coefficients βv 
and βw can be estimated, given by: 
 
 Equation 2 
  
 Equation 3 
Using these solutions, for the data in figure 3, βv, reduces 
from ~0.86 at slow scan rate to around 0.36 for scan rates 
≥ 0.2 V/s. This agrees well with βw obtained from 
equation (3), which tends to ~0.4(±0.1) at high scan rate. 
According to Klingler and Kochi, good agreement 
between βw and βv  (correlated with a reversibility factor 
< 0.5) allows the electron-transfer rate constant at the CV 
peak potential k(Ep) to be obtained and thence the 
heterogeneous standard rate constant, ks  according to: 
 
Assuming a diffusion coefficient, D, of 1.7 x 10
-6 cm2 s-1, 
this yields ks ~5x10
-3 cm s-1.  This result is also confirmed 
by the technique of Gileadi and Eisner [19] which uses 
the intersect (vc, figure 3(b)) obtained by extrapolation of 
the linear fits to the low scan rate data (Epc vs lnv) and the 
high scan rate data. Figure 3(b) shows the peak potential 
for anodic and cathodic peak as a function of scan speed 
(x axis: lnv) and as a function of FeMJ concentration 
(shaded areas in figure for anodic and cathodic branch). 
As can be seen in this figure, at higher FeMJ 
concentration, the critical scan rate, vc obtained from this 
intersect for both anodic and cathodic peaks converge and 
have a relation with ks according to [19]: 
 
 
 
 
Fig. 3. (a) CV of referration of DFMJ by titration with 
Fe(acac)3; 200mV/s in DMSO, 0.1 M LiCl. Ep versus ln ν: (b) 
FeMJ (50-650µM). Bounds of the upper and lower 
concentration data are indicated by the shaded areas. (c) 
0.5 mM FeMJ with addition of 50-800µM(excess) Fe(acac)3. 
Solid lines in (b) and (c) give linear trend lines for the low and 
high scan rate data, the intersection gives the critical scan rate 
(νc). 
which yields ks~9x10
-3 cm s-1.  
 
Based on these findings, quasi reversible 
electrochemistry is confirmed under these conditions and 
chemical reversibility is dependent on the concentration 
ratio of Fe3+, Fe2+ and DFMJ and reaches a maximum for 
DFMJ:Fe3+ > 1. So, the CV will be dependent on [Fe3+] 
according to the equilibrium described by k1/k-1 and k2 /k-
2 (scheme 1) and taking into account that Fe
2+ will be 
βv =
2.3RT
2nF
dE p
d logv
 
 
 
 
 
 
−1
βw =
1.85RT
nF
E p − E p / 2[ ]
−1
ks = 2.18
DβnFυ
RT
 
 
 
 
 
 
1/ 2
exp −
β2nF
RT
E pa − E pc( )
 
 
 
 
 
 
ks = −0.48β + 0.52 + ln
DβnFυc
RT
 
 
 
 
 
 
1/ 2
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produced at the electrode at the FeMJ redox potential in 
the presence of solution Fe3+.  
Fig. 4 CV’s of bovine urine after Sep-Pak tC18 elution from  (a) 
cows (G1, G2, G3) spiked with 600µM FeMJ. (b) cow C3: 
NEG1 unfiltered; NEG2 0.22µm filtered; POS1 unfiltered 
spiked with 500µMFeMJ; POS2 spiked with 500µMFeMJ and 
then filtered; POS3  filtered and then spiked with 500µMFeMJ; 
background is dotted line. (c) Background subtracted CVs with 
600µM FeMJ added together with 0 - 200µM Fe(acac)3; 
200mV/s. in DMSO with 0.1 M LiCl 
 
3.3 Bovine urine-sample electrochemistry 
Data from spiked filtered cow’s urine samples (figure 4) 
show a well-resolved FeMJ redox peak.  Nevertheless, 
despite the same concentration of FeMJ, the peak-height 
for each sample is different, as can be seen in figure 4a. 
Based on the calibration in figure 2a, recovery rates for 
spiked urine were typically found in the range 40-100%, 
suggesting a matrix effect, influencing the equilibria in 
scheme 2.  
The ferric mycobactins can also be detected by their 
characteristic absorbance around 450 nm, indicative of 
iron-containing compounds [9]. Samples from three 
exemplar cows with and without the same concentration 
of added FeMJ also produce different increases in 
absorbance as seen in figure 5b. 
 If the sample matrix influences the FeMJ complex 
stability (scheme 2), this is not altogether surprising since 
the absorbance will be influenced by availability of free 
Fe2+/3+ in the sample.  Figure 5a shows the development 
of the 452nm peak for DFMJ in the presence of ferric 
chloride, which highlights the 1:1 stoichiometry between 
Fe and MJ, as predicted also from the electrochemistry 
and demonstrates how the absorbance measured will 
depend on the free Fe3+. Furthermore, mycobactins have 
a strong amphipathic character, whose solubility and 
dispersion in urine will depend on other content. This 
will also influence the apparent concentration measured 
and the ferric mycobactin complex equilibrium. 
Conventionally, mycobactins have been thought to be 
associated with the cell wall and membrane of the 
mycobacteria. They have low solubility in water (5-10 
µg/mL) [14], and upon binding iron, the hydrophilic 
peptidic head is turned inward to coordinate the central 
iron atom [20] creating a more compact, less flexible 
conformation, but with the external surface dominated by 
the lipophilic character of the alkyl chain. Research on 
related siderophores, the marinobactins, has shown that 
the desferri form of the siderophore is capable of forming 
micelles [21]. The marinobactins have a more overall 
hydrophilic character than mycobactins, but share the 
attribute of a single C12-16 alkyl chain, making them 
highly amphipathic. This gives rise to a conical molecular 
shape in which the hydrophilic iron-coordinating ligands 
are spread out on the surface of the micelle. Upon 
binding iron, marinobactins undergo a phase change to 
form bilayered vesicles [21].  
T he issue is especially highlighted for urine sample C3.  
An unfiltered sample of C3 shows considerable 
background absorbance in the range from 350-500nm 
which could be taken for mycobactin infection. Although 
TB reactors had been seen in the heard previously, the 
herd had been tested clear before the samples were taken. 
Notwithstanding this, the full environmental and 
immunological scope of commonly found mycobacteria 
remains largely unexplored, and many types of 
mycobacteria have been isolated from cultivated land in 
England, including the known mycobactin producers M. 
aurum, M. fortuitum, M. intercellulare, M. kansasii, M. 
marinum, M. phlei, M. scrofulaceum, M. smegmatis, 
thermoresistibile, and others [22]. Current tests for the 
pathogenic strains of M. bovis are not targeted to these 
other environmental organisms, though false positive 
tests for paratuberculosis in the faeces of ruminants have 
been known to occur experimentally [23]. Furthermore, 
testing for Johne’s disease is not routinely carried out, 
given the cumbersome nature of current methods, which 
rely on culturing the slow-growing organism in the 
presence of exogenous mycobactin. However, a case of 
Johne’s disease was detected in the herd a few months 
after these samples were taken. 
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Passing the C3 sample through a 0.22µm filter (which 
also removes any bacterial infection) reduced the 
absorbance in this region (compare curves NEG1 and 
NEG2 in figure 5c), but this filter also removes the FeMJ 
(compare C3 with 500µM added FeMJ before (POS1) 
and after filtration (POS2), figure 5c). Nevertheless, the 
same concentration of FeMJ added after filtration (POS3) 
gives a clear absorbance around 450nm, but this is still 
prone to background sample effects on the measurement. 
Looking at the electrochemistry of this sample (figure 4b) 
also shows conflicting estimates of FeMJ and 
interestingly, there is a small peak in the NEG1 sample, 
which has no added FeMJ. This agrees with the 
absorbance date in figure 5b and c, which may be 
indicative of mycobactin. 
In view of these potential matrix effects and presuming 
that the sample matrix disturbs the equilibria in scheme 2, 
a strategy for signal ‘normalisation’ is proposed. The 
effect on the peak currents in the CV (figure 4c) can be 
seen for a sample spiked with 600µM FeMJ, with added 
Fe(acac)3. This demonstrates the shift in the equilibrium 
(scheme 2) as a result of free Fe2+/3+. Taking this 
initiative, added Fe(acac)3 can be seen to increase the 
peak-heights for the spiked urine samples recorded in 
figure 4a (figure 6). From these results, the predicted 
concentration of FeMJ measure from the shaded area in 
figure 6, would be 580±25µM whereas from the peak-
heights taken from figure 4a only 240±15µM FeMJ was 
estimated in the assay. This method, which takes into 
account the kinetics of the FeMJ complex formation, 
yields estimates >90% of the spiked FeMJ concentration, 
compared with the outcome without added Fe(acac)3 of 
40±10%. 
 
 
Fig.6 Peak height measured from the oxidation and reduction 
peaks in the cyclic voltammogram (200mV/s. in DMSO with 
0.1 M LiCl) for urine samples G1, G2 and G3 spiked with 
600µM FeMJ. CV’s recorded with and without added Fe(acac)3
 
(x axis). 
Fig 5. UV-Vis absorption spectra measured in methanol for (a) titration for ferric chloride (0 – 50 µM) into deferrated MJ 
(DFMJ). (b) samples of bovine urine Sep- ak tC18 eluates in 0.75 mL methanol; C1-C3 refer to samples take from three 
individual cows with and without the addition of 2 µM FeMJ. (c) Analysis of Sep-Pak tC18 eluates from the bovine urine samples 
from a single urine pool and treated as described in materials and methods. 
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4. Conclusions  
This assay, based on iron-chelated mycobactin, exploits 
the high affinity of mycobactins for Fe3+. This enables the 
Fe3+/2+ electrochemistry to be used as an indicator of the 
presence of mycobactin.  The redox potential is 
dependent on the mycobactin and pFe value for the 
ligand [15]. This is well separated from the uncomplexed 
Fe3+/2+ electrochemistry making the identification 
possible. Nevertheless, the difference in affinity of 
mycobactin between the Fe3+ and Fe2+ creates an EC 
mechanism, which is influenced by the Fe3+/2+ 
concentrations in solution and disturbed by the sample 
matrix.  This has the capacity to affect the peak currents 
for the siderophore complexed Fe3+/2+, as a result of the 
equilibrium position in scheme 2.  Nevertheless, addition 
of an excess of Fe(acac)3 to the sample pushes that 
equilibrium towards the siderophore complex, allowing a 
more reliable and quantitative assay of mycobactin J to 
be demonstrated, even in different urine samples with a 
significant matrix effect.   
As mentioned earlier, analysis for many mycobactins is 
not straightforward, so not undertaken routinely. A 
simple electrochemical assay for mycobactin could serve 
as a diagnostic. Furthermore, aside from the pathogenic 
disease role, some mycobactins have also been 
investigated for a variety of therapeutic applications 
spanning from chelation therapy agents and anti-cancer 
agents to antimicrobials. Chelation therapy is used to 
treat conditions that arise due to undesirable or excess 
quantities of metal within the body. These can include 
therapies for heavy metal toxicity [24] and the removal of 
internal radioactive contamination. Treatment for the 
removal of excess iron is the most common type of 
chelation therapy and is routinely carried out for the 
treatment of acute iron poisoning and chronic iron 
overload, such as hemochromatosis [25]. Deferoxamine, 
deferasirox, and deferiprone are all pharmaceutical agents 
in use for iron-specific chelation therapy. The first of 
these agents, deferoxamine, was originally discovered as 
the siderophore of Streptomyces pilosus. Because of the 
disruption that aggressive iron chelation could have on 
iron homeostasis, it is desirable to closely monitor 
concentrations of the therapeutic mycobactin and its 
chelated iron content upon excretion. Thus, the 
electrochemical assay investigated in the research 
reported here could have capability to be developed into a 
simple urine test to monitor dosage. Pharmaceutical 
companies have been increasingly turning to companion 
diagnostics as a means to improve safety and efficacy of 
new prospective pharmaceuticals [26]. 
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